Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: A clinical practice observational study of patients who discontinued treatment

Rheumatology International

Volumn 34, Issue 8, 2014, Pages 1053-1057

  Iglesias, Estíbaliz ^a   Torrente Segarra, Vicenç ^a   Bou, Rosa ^a   Ricart, Silvia ^a   González, María Isabel ^a   Sánchez, Judith ^a   Calzada, Joan ^a   Antón, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anti TNF; Disease activity; Juvenile idiopathic arthritis; Outcome

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS; ARTHRITIS, JUVENILE; BLOOD; DRUG ADMINISTRATION; IMMUNOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TIME;

ANTIBODIES, ANTINUCLEAR; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, JUVENILE; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; HUMANS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904855345     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2884-z     Document Type: Article

References (11)

1. Beukelman T, Patkar NM, Saag KG et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthr Care Res 63(4):465-482
2. Prince FHM, Twilt M, Simon SCM et al (2009) When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 68(7):1228-1229
3. Pratsidou-Gertsi P, Trachana M, Pardalos G et al (2010) A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. Clin Exp Rheumatol 28(6):919-922
4. Remesal A, De Inocencio J, Merino R et al (2010) Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol 37(9):1970-1971
5. Baszis K, Garbutt J, Toib D et al (2011) Clinical outcomes after withdrawal of anti-tumor necrosis factor á therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. Arthr Rheum 63(10):3163-3168
6. Postepski J, Kobusinska K, Olesinska E et al (2012) Clinical remission in juvenile idiopathic arthritis after termination of etanercept. Rheumatol Int 21 Jul [Epub ahead of print]
7. Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390-392
8. Wallace CA, Ruperto N, Giannini E (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31(11):2290-2294
9. Ravelli A, Varnier GC, Oliveira S et al (2011) Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthr Rheum 63(1):267-275
10. Ravelli A, Felici E, Magni-Manzoni S (2005) Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthr Rheum 52(3):826-832
11. Felici E, Novarini C, Magni-Manzoni S et al (2005) Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. J Rheumatol 32(9):1805-1810